Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery
Study Details
Study Description
Brief Summary
This phase II study evaluates radioiodine planar and SPECT/CT imaging with iodine-123 in patients with follicular thyroid nodules prior to surgery. Because biopsy alone is not sufficient to distinguish between malignant follicular thyroid nodules and benign follicular thyroid nodules, patients with follicular thyroid lesions are referred for surgery for further evaluation. A non-invasive imaging method that can accurately determine malignancy in follicular thyroid nodules would be valuable in patient management and could potentially spare patients unnecessary surgery. Planar imagine uses a gamma camera to obtain 2D images and SPECT/CT imaging is a special type of CT scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the tumor cells. Radioiodine planar and SPECT/CT imaging may be more accurate in distinguishing between benign follicular thyroid nodules and malignant follicular thyroid nodules to help reduce the need for surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
PRIMARY OBJECTIVES:
-
Determine the proportion of benign nodules appearing as hot/warm on radioiodine scans (nodule uptake >= uptake in normal thyroid tissues).
-
To identify a possible relationship between iodine-123 (I-123) uptake on planar and single-photon emission computerized tomography (SPECT)/computerized tomography (CT) images and malignancy on surgical pathology in thyroid nodules which were previously identified by fine-needle aspiration (FNA) as indeterminate follicular neoplasms.
-
Examine correlations between intensity of uptake in follicular nodules before surgery (standard uptake values [SUV] on the quantitative reconstructions from our Veriton SPECT/CT scanner and nodule-to-normal thyroid background ratios on planar and SPECT images) and pathology findings and determine an SUV threshold that best distinguishes between benign and malignant nodules.
-
Compare the usefulness of conventional planar imaging versus SPECT/CT imaging for thyroid nodules, in order to inform our optimal clinical protocol.
-
Establish an imaging protocol best suited for measuring uptake in small thyroid nodules.
OUTLINE:
Patients receive iodine-123 orally (PO) and then undergo planar imaging and a SPECT/CT scan on study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Observational (I-123, planar imaging, SPECT/CT scan) Patients receive iodine-123 PO and then undergo planar imaging and a SPECT/CT scan on study. |
Procedure: Computed Tomography
Undergo a SPECT/CT scan
Other Names:
Radiation: Iodine I-123
Given PO
Other Names:
Procedure: Planar Imaging
Undergo planar imaging
Procedure: Single Photon Emission Computed Tomography
Undergo a SPECT/CT scan
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of adverse events [Up to study completion, up to one year]
Adverse events will be assessed while patients are in the nuclear medicine division undergoing positron emission tomography/computed tomography imaging.
- Iodine-123 uptake [Up to study completion; up to one year]
We will compare the intensity of uptake in malignant versus benign lesions.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age > 18 years
-
Any gender
-
Negative urine pregnancy test within 48 hours before the administration of radiopharmaceutical in women under 55
-
Bethesda IV cytopathology on biopsy of thyroid nodule
-
Any outside FNA reports have to be reviewed by Mayo pathologist
-
Nodules 1-4 cm with solid appearance on ultrasound
-
Ultrasound images and report documented in medical record, including the size of the nodule and location (upper, mid or lower portion of the thyroid lobe)
-
At least 2/3 of either thyroid lobe without nodules should be present to allow for the measurement of uptake in unaffected thyroid tissue
-
Thyroid stimulating hormone (TSH) 0.3-2.0 mIU/L
-
Patient scheduled for surgical resection of the nodule
-
I-123 planar and SPECT/CT can be scheduled at least 2-3 days after biopsy and before surgery
Exclusion Criteria:
-
Recent iodinated contrast, including intravenous (IV) and oral CT contrast or interventional vascular or cardiac study (within 6 weeks)
-
Current thyroid hormone supplementation
-
Current use of anti-thyroid medications (methimazole or propylthiouracyl)
-
Less than 2-3 days after thyroid nodule FNA/biopsy
-
Presence of another nodule of similar size in the same area of thyroid lobe, which could impair localization of the nodule on positron emission tomography (PET)/CT images
-
Less than 2/3 of normal thyroid tissue present in either thyroid lobe without nodules
-
Positive pregnancy test
-
All women who are breastfeeding
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: Jolanta M Durski, Mayo Clinic in Rochester
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20-010663
- NCI-2022-03573